Company Overview and News
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for canakinumab as a potential treatment for cardiovascular risk reduction.
AUROPHARMA 524804 ARBQY
The equity market opened on a cautious note but managed to close in the positive after buying in last hour of trade on October 15. It was a volatile session of trade for Nifty but it managed to close at 10,512 up by 0.38 percent.
SIFLY 523756 SRI AUROPHARMA HDB SREINFRA 524804 500180 ARBQY HDFCBANK SRIA
Merger and acquisition (M&A) deal values recorded a 5.3-times increase year-on-year (y-o-y) in the third quarter of calendar year 2018 (Q32018) driven by outbound activity, according to a dealtracker report by Grant Thornton. The report stated that M&A deal values stood at $11.506 billion in Q32018 compared with $2.147 billion in the same period last year.
CNACU AUROPHARMA 524804 ARBQY CNAC
(Reuters) - European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.
AUROPHARMA 524804 ARBQY
Corporate India announced merger and acquisitions (M&As) worth $11.5 billion in the third quarter of this year, following which the January-September deal tally stood at $76.03 billion, says a report.
BHRYY CNACU AUROPHARMA 534816 524804 ARBQY CNAC INFRATEL
As part of its efforts to promote generic competition and reduce healthcare costs, the USFDA has released guidance documents to advance the development of copycats for complex drugs.
532321 AUROPHARMA NATCOPHARM 524804 ARBQY 524816 CDLYY CADILAHC
Aurobindo Pharma Ltd Thursday said it would be making and marketing azithromycin oral suspension in the US market after getting final approval from the US Food and Drug Administration (USFDA). The oral suspension is to treat mild-to-moderate infections, a press release said here.
PFZ AUROPHARMA 524804 ARBQY 500680 PFE PFIZER
Drug firm Aurobindo Pharma on Thursday said it has received final nod from the US health regulator for its Azithromycin oral suspension used for treatment of infections.
AUROPHARMA 524804 ARBQY
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY
Aurobindo Pharma is one of the few large generic players to post growth in its US business, whereas similar-sized portfolios have witnessed significant erosion. With near-term opportunities such as Toprol XL, Prevacid ODT, Welchol, and several injectable products, we believe APL could continue to maintain its growth momentum.
GRASIM GRSXY GRSJY AUROPHARMA 524804 ARBQY 500300
The Indian stock market is trading on a flat note in the afternoon session with the Nifty50 down marginally by 3 points, trading at 10,344 while the Sensex has lost over 24 points at 34,450.
BAJAJ-AUTO 500325 524816 DABUR PRMQY 538268 DBRQY 500096 500696 BJJQY 500570 500493 EICHERMOT WONDERLA BHARATFORG RLNIY TVSMOTOR 524804 511072 UNITDSPR YYBKY 532432 DHFL BAJFINANCE TATASTEEL TATLY UQNTY 500302 523204 AUROPHARMA GODREJIND 533150 RELIANCE HINDUNILVR 532977 BHRQY ABAN 505200 532343 500470 NATCOPHARM RIGD BHARTIARTL TATAMOTORS 500034 YESBANK ECQRY 532648 PEL 532454 GODREJPROP TTST ARBQY 500164 TTM
The Indian benchmark indices are trading on a positive note this Tuesday morning with the Nifty50 adding 26 points, trading at 10,374 while the Sensex has gained over 100 points at 34,576.
BAJAJ-AUTO GOACARBON 500325 524816 UBL PRMQY 532636 IIFL 538268 533137 532478 CADILAHC DEN 535789 532321 AJANTPHARM LHFLY 500570 500493 EICHERMOT WONDERLA 500253 BHARATFORG RLNIY 524804 533282 511072 532508 YYBKY DHFL TATASTEEL TATLY LICHSGFIN 500302 507458 523204 AUROPHARMA 533150 RELIANCE 532977 BHRQY ABAN 505200 500470 NATCOPHARM RIGD JSL BHARTIARTL TATAMOTORS 509567 GRAVITA YESBANK ECQRY HINDALCO IDKQY UBHOLDINGS 532648 UNBWY CDLYY PEL IBULHSGFIN 532454 HNDNF GODREJPROP 532331 TTST ARBQY 500440 TTM
Dalal Street is witnessing a cat and mouse game as the market has recovered with the Nifty50 adding 2 points, trading at 10,318 while the Sensex has shed 14 points at 34,362.
BAJAJ-AUTO IOC GOACARBON 500325 JIPKY PRMQY 532636 IIFL JSWENERGY 539437 CADILAHC 532321 GAILF 500493 BHARATFORG RLNIY SBAZ EXIDEIND TVSMOTOR 524804 UNITDSPR APOLLOTYRE YYBKY AYRQY 530965 517334 532432 EXQDY TATASTEEL TATLY GAILY KOTAKBANK UQNTY 500302 523204 500188 HINDZINC AUROPHARMA 533150 GODREJIND RELIANCE 533273 HNDZY 532977 ABAN 532343 MOZTY 500470 532187 IDFCBANK RIGD 503100 509567 YESBANK INDIGO HINDALCO PHOENIXLTD INDUSINDBK KMBKY 500877 IBN 532648 JPASSOCIAT CDLYY 533148 PEL 539448 532532 HNDNF ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY MOTHERSUMI 532174 ARBQY 500247 500086 500164 500440
The bears continue to hold a firm grip of the Indian stock market as the Nifty50 continues to trade lower by 198 points and is trading at 10,660 while the Sensex has plunged 650 points at 35,325.
IOC 500408 PAGEIND MUTHOOTFIN 500325 UBL TCHQY FEDA 532755 532478 CADILAHC 532321 534816 UCLQY FEDS GAILF FEDERALBNK EICHERMOT RLNIY PGDQY AXB 524804 511072 532827 532749 FDBAY APOLLOTYRE AYRQY 530965 517334 MRZUY ULTRACEMCO 532500 TECHM 500182 AXBA DHFL MARUTI 500180 GAILY KOTAKBANK TCS 507458 BHRYY AUROPHARMA 500469 GODREJIND 539254 RELIANCE 533273 532538 533155 533398 BHRQY TTNQY JUBLFOOD 532215 505200 MOZTY 532540 532187 AXISBANK ALLCARGO RIGD JBLWY INFRATEL HDFCBANK HEROMOTOCO BHARTIARTL ADANITRANS INDIGO ECQRY INDUSINDBK KMBKY 500877 IBN UBHOLDINGS UCLQF UNBWY CDLYY 539448 AXBKY 532454 ICICIBANK OBZIY OBEROIRLTY MOTHERSUMI HDB 532174 ARBQY TATAELXSI HRTQY 500247 500164
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...